Trial Profile
Open-Label, Randomized, Multi-Center Study Comparing the Sequence of High Dose Aldesleukin (Interleukin-2) and Ipilimumab (Yervoy) in Patients With Metastatic Melanoma
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 07 Dec 2023
Price :
$35
*
At a glance
- Drugs Aldesleukin (Primary) ; Interleukin-2 (Primary) ; Ipilimumab (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Acronyms PROCLIVITY 02
- Sponsors Prometheus Laboratories
- 14 Nov 2023 Study design changed from crossover to sequential.
- 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
- 16 Jul 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.